| Liver carcinoma
Lenvima vs Tecentriq
Side-by-side clinical, coverage, and cost comparison for liver carcinoma.Deep comparison between: Lenvima vs Tecentriq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecentriq has a higher rate of injection site reactions vs Lenvima based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecentriq but not Lenvima, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lenvima
Tecentriq
At A Glance
Oral
Once daily
Multi-kinase inhibitor
IV infusion
Every 2-4 weeks
PD-L1 antagonist
Indications
- Differentiated Thyroid Gland Carcinoma
- Renal Cell Carcinoma
- Liver carcinoma
- Endometrial Carcinoma
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
Dosing
Differentiated Thyroid Gland Carcinoma 24 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (first-line, with pembrolizumab) 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity or up to 2 years.
Renal Cell Carcinoma (previously treated, with everolimus) 18 mg orally once daily in combination with everolimus 5 mg orally once daily until disease progression or unacceptable toxicity.
Liver carcinoma 12 mg orally once daily for patients >=60 kg or 8 mg orally once daily for patients <60 kg, until disease progression or unacceptable toxicity.
Endometrial Carcinoma 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression.
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dysphonia, hypothyroidism, hemorrhagic events, rash, musculoskeletal pain.
Serious Hepatic encephalopathy, hepatic failure, cardio-respiratory arrest, sepsis, myocardial infarction, pneumonitis, acute kidney injury, renal failure, dehydration, thrombocytopenia, dyspnea, anemia.
Postmarketing Pancreatitis, impaired wound healing, cholecystitis, nephrotic syndrome, arterial aneurysms/dissections/rupture.
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Pharmacology
Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 kinase activities as well as FGFR1-4, PDGFRA, KIT, and RET, suppressing pathogenic angiogenesis and tumor growth; in combination with pembrolizumab or everolimus, it demonstrates enhanced antiangiogenic and antitumor activity.
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lenvima
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Lenvima
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lenvima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lenvima.
No savings programs available for Tecentriq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LenvimaView full Lenvima profile
TecentriqView full Tecentriq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.